Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Qutenza · 1 trial · 2 indications
Patients will record the maximum intensity of pain (0-10) each day after placing an infusion site in a diary with which they are already comfortable. They will record the score each day for 14 days unless they have recorded "0" for two consecutive days. The primary outcome measure will be the average of those 14 maximum intensity pain scores (the sum of the maximum for each day divided by the number of days, generally 14; range 0-10).
| Arm | Type | Description |
|---|---|---|
| Qutenza patch | EXPERIMENTAL | All participants actively treated with Qutenza |
| Name | Type | Description |
|---|---|---|
| Qutenza (8% capsaicin) | DRUG | We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin. |
Inclusion Criteria: * Pulmonary Hypertension * Using subcutaneous treprostinil * Already participating as a subject in our prospective study of infusion site pain * Has documented debilitating pain (6/10 or greater) in the study after a site change Exclusion Criteria: * Uncontrolled hypertension ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
Qutenza is a small molecule being studied for the treatment of pulmonary hypertension and pulmonary arterial hypertension. It is delivered as a patch and is currently in Phase 2 clinical development for this indication. The drug is being developed by United Therapeutics Corporation.
Qutenza is a small molecule delivered via a patch. It is being investigated for its potential to treat pulmonary hypertension, a condition characterized by high blood pressure in the lungs. The specific molecular target of Qutenza has not been disclosed in the available information.
Qutenza is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research on Qutenza as a potential treatment for pulmonary hypertension.
Qutenza is in Phase 2 clinical development for pulmonary hypertension. A Phase 2 clinical trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities for this indication.
Qutenza has been studied in one completed Phase 2 clinical trial with the identifier NCT01260454. The trial, titled "The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain," enrolled 6 participants in the United States and included patients with pulmonary hypertension and pulmonary arterial hypertension.
Qutenza is a patch formulation of a small molecule. It is being investigated for use in pulmonary hypertension, specifically to address pain associated with treprostinil infusion. The active ingredient and any alternative names for Qutenza have not been specified in the available information.